Analysis of JAK2V617F mutation in Chinese patients with myeloproliferative disorders

7Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

It is now well-recognized that the activating JAK2V617F mutation occurs in the majority of patients with polycythemia vera (PV) and approximately half of those with either essential thrombocythemia (ET) or myelofibrosis with myeloid metaplasia (MMM). Here we analyzed JAK2 V617F mutation in 137 Chinese patients with myeloproliferative disorders by allele-specific polymerase chain reaction (PCR). DNA was extracted from methanol/acetic acid-fixed cells that had been routinely prepared for cytogenetic analysis. A single point mutation (Val617Phe) was identified in JAK2 in 42 (73.7%) of 57 patients with PV, 40 (58.8%) of 68 with ET, and eight (66.7%) of 12 with MMM. © 2007 Wiley-Liss, Inc.

Cite

CITATION STYLE

APA

Chen, S., Fei, H., Zhang, R., Xue, Y., Pan, J., Wu, Y., & Ceng, J. (2007). Analysis of JAK2V617F mutation in Chinese patients with myeloproliferative disorders. American Journal of Hematology, 82(6), 458–459. https://doi.org/10.1002/ajh.20872

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free